GlassScriptPhysician profile
Marc Braunstein
NPI 1568761336
$112,833.23
in general payments reported to CMS, 2019-2025
37 companies · $4,955 in 2025
The $4,955 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,383 · 2020: $22K · 2021: $18K · 2022: $21K · 2023: $19K · 2024: $24K · 2025: $4,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,745 · Travel and Lodging: $1,745 · Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,212.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,745.00 |
| Travel and Lodging | $1,744.92 |
| Food and Beverage | $1,513.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20,624.62 | 2019-2024 | Darzalex, Tecvayli, Carvykti |
| Celgene Corporation | $15,991.67 | 2019-2023 | Pomalyst |
| Abbvie INC. | $11,387.50 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $10,519.73 | 2019-2025 | Lumoxiti, Calquence, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $9,175.11 | 2020 | |
| Seagen INC. | $8,569.42 | 2021-2023 | Adcetris |
| Genzyme Corporation | $7,177.13 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,395.00 | 2022-2024 | |
| Incyte Corporation | $3,145.00 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $2,800.00 | 2023-2025 | Carvykti, Talvey |
| Glaxosmithkline, LLC. | $2,791.98 | 2021-2025 | Ojjaara |
| Adc Therapeutics America, INC. | $2,500.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $2,180.21 | 2024 | Tazverik |
| Cti Biopharma Corp. | $1,962.88 | 2022-2023 | Vonjo |
| Pfizer INC. | $1,750.00 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,175.00 | 2024-2025 | Vanflyta, Enhertu |
| Adaptive Biotechnologies Corporation | $1,085.34 | 2021-2025 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $1,000.00 | 2022 | |
| Beigene USA, INC. | $731.64 | 2022-2024 | Brukinsa |
| Epizyme, INC. | $675.00 | 2022 | |
| Janssen Global Services, LLC | $620.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $374.51 | 2024-2025 | Ultomiris |
| Aurobindo Pharma USA, INC. | $250.00 | 2020 | |
| Sobi, INC | $200.00 | 2024 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Genmab U.S., INC. | $119.42 | 2023-2024 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2020 | |
| Janssen Research & Development, LLC | $80.00 | 2025 | Darzalex, Tecvayli |
| Astellas Pharma US INC | $62.31 | 2025 | Cresemba |
| Taiho Oncology, INC. | $33.83 | 2025 | |
| Merck Sharp & Dohme LLC | $33.31 | 2025 | Keytruda Qlex, Keytruda |
| Beone Medicines USA, INC. | $30.44 | 2025 | Brukinsa |
| Geron Corporation | $25.48 | 2025 | Rytelo |
| Amgen INC. | $19.79 | 2021 | |
| Kite Pharma, INC. | $17.73 | 2024 | Yescarta |
| Lilly USA, LLC | $16.31 | 2024 | Jaypirca, Verzenio |
| Karyopharm Therapeutics INC. | $13.87 | 2025 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Braunstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.